Glucocorticoid-induced osteoporosis: Lessons from Cushing's syndrome

Clinical Endocrinology

Volumn 79, Issue 1, 2013, Pages 1-11

  Tõth, Miklõs ^a   Grossman, Ashley ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; GLUCOCORTICOID; PARATHYROID HORMONE[1-34];

BONE CELL; BONE DENSITY; BONE FRAGILITY; BONE MINERAL; BONE TURNOVER; CUSHING SYNDROME; DRUG INDUCED DISEASE; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; HUMAN; HYPERCORTISOLISM; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW;

BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CUSHING SYNDROME; GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84878540184     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/cen.12189     Document Type: Review

References (86)

1. Cushing, H., (1932) The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bulletin Johns Hopkins Hospital, 50, 137-195.
2. Newell-Price, J., Bertagna, X., Grossman, A.B., et al,. (2006) Cushing's syndrome. Lancet, 367, 1605-1617.
3. van Staa, T.P., Leufkens, H.G., Abenhaim, L., et al,. (2000) Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford), 39, 1383-1389.
4. Hermus, A.R., Smals, A.G., Swinkels, L.M., et al,. (1995) Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism, 80, 2859-2865.
5. Tauchmanova, L., Pivonello, R., De Martino, M.C., et al,. (2007) Effects of sex steroids on bone in women with subclinical or overt endogenous hypercortisolism. European Journal of Endocrinology, 157, 359-366.
6. Futo, L., Toke, J., Patocs, A., et al,. (2008) Skeletal differences in bone mineral area and content before and after cure of endogenous Cushing's syndrome. Osteoporosis International, 19, 941-949.
7. Barahona, M.J., Sucunza, N., Resmini, E., et al,. (2009) Deleterious effects of glucocorticoid replacement on bone in women after long-term remission of Cushing's syndrome. Journal of Bone and Mineral Research, 24, 1841-1846.
8. Tauchmanova, L., Pivonello, R., Di Somma, C., et al,. (2006) Bone demineralization and vertebral fractures in endogenous cortisol excess: role of disease etiology and gonadal status. Journal of Clinical Endocrinology and Metabolism, 91, 1779-1784.
9. Mancini, T., Doga, M., Mazziotti, G., et al,. (2004) Cushing's syndrome and bone. Pituitary, 7, 249-252.
10. Kawamata, A., Iihara, M., Okamoto, T., et al,. (2008) Bone mineral density before and after surgical cure of Cushing's syndrome due to adrenocortical adenoma: prospective study. World Journal of Surgery, 32, 890-896.
11. van der Eerden, A.W., den Heijer, M., Oyen, W.J., et al,. (2007) Cushing's syndrome and bone mineral density: lowest Z scores in young patients. Netherlands Journal of Medicine, 65, 137-141.
12. Lekamwasam, S., Adachi, J.D., Agnusdei, D., et al,. (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporosis International, 23, 2257-2276.
13. Camozzi, V., Sanguin, F., Albigier, N., et al,. (2010) Persistent increase of osteoprotegerin levels after cortisol normalization in patients with Cushing's syndrome. European Journal of Endocrinology, 162, 85-90.
14. Pivonello, R., De Leo, M., Vitale, P., et al,. (2010) Pathophysiology of diabetes mellitus in Cushing's syndrome. Neuroendocrinology, 92 (Suppl 1), 77-81.
15. Thrailkill, K.M., Lumpkin, C.K. Jr, Bunn, R.C., et al,. (2005) Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. American journal of Physiology Endocrinology and Metabolism, 289, E735-E745.
16. Hardy, R., &, Cooper, M.S., (2010) Adrenal gland and bone. Archives of Biochemistry and Biophysics, 503, 137-145.
17. Weinstein, R.S., (2011) Clinical practice. Glucocorticoid-induced bone disease. New England Journal of Medicine, 365, 62-70.
18. Canalis, E., Mazziotti, G., Giustina, A., et al,. (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporosis International, 18, 1319-1328.
19. Pierotti, S., Gandini, L., Lenzi, A., et al,. (2008) Pre-receptorial regulation of steroid hormones in bone cells: insights on glucocorticoid-induced osteoporosis. Journal of Steroid Biochemistry and Molecular Biology, 108, 292-299.
20. Dovio, A., Perazzolo, L., Saba, L., et al,. (2006) High-dose glucocorticoids increase serum levels of soluble IL-6 receptor alpha and its ratio to soluble gp130: an additional mechanism for early increased bone resorption. European Journal of Endocrinology, 154, 745-751.
21. Rochefort, G.Y., Pallu, S., &, Benhamou, C.L., (2010) Osteocyte: the unrecognized side of bone tissue. Osteoporosis International, 21, 1457-1469.
22. Abu, E.O., Horner, A., Kusec, V., et al,. (2000) The localization of the functional glucocorticoid receptor alpha in human bone. Journal of Clinical Endocrinology and Metabolism, 85, 883-889.
23. Cooper, M.S., Walker, E.A., Bland, R., et al,. (2000) Expression and functional consequences of 11beta-hydroxysteroid dehydrogenase activity in human bone. Bone, 27, 375-381.
24. Morrison, N.A., Shine, J., Fragonas, J.C., et al,. (1989) 1,25-dihydroxyvitamin D-responsive element and glucocorticoid repression in the osteocalcin gene. Science, 246, 1158-1161.
25. Ueland, T., Bollerslev, J., Godang, K., et al,. (2001) Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess-possible role in bone homeostasis. European Journal of Endocrinology, 145, 685-690.
26. Kristo, C., Ueland, T., Godang, K., et al,. (2008) Biochemical markers for cardiovascular risk following treatment in endogenous Cushing's syndrome. Journal of Endocrinological Investigation, 31, 400-405.
27. Lekva, T., Bollerslev, J., Kristo, C., et al,. (2010) The glucocorticoid-induced leucine zipper gene (GILZ) expression decreases after successful treatment of patients with endogenous Cushing's syndrome and may play a role in glucocorticoid-induced osteoporosis. Journal of Clinical Endocrinology and Metabolism, 95, 246-255.
28. Lekva, T., Ueland, T., Boyum, H., et al,. (2012) TXNIP is highly regulated in bone biopsies from patients with endogenous Cushing's syndrome and related to bone turnover. European Journal of Endocrinology, 166, 1039-1048.
29. Gross, K.L., Lu, N.Z., &, Cidlowski, J.A., (2009) Molecular mechanisms regulating glucocorticoid sensitivity and resistance. Molecular and Cellular Endocrinology, 300, 7-16.
30. Wang, F.S., Wu, R.W., Ko, J.Y., et al,. (2011) Heat shock protein 60 protects skeletal tissue against glucocorticoid-induced bone mass loss by regulating osteoblast survival. Bone, 49, 1080-1089.
31. Kalpakcioglu, B.B., Engelke, K., &, Genant, H.K., (2011) Advanced imaging assessment of bone fragility in glucocorticoid-induced osteoporosis. Bone, 48, 1221-1231.
32. Chiodini, I., Carnevale, V., Torlontano, M., et al,. (1998) Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess: study in eumenorrheic patients with Cushing's syndrome. Journal of Clinical Endocrinology and Metabolism, 83, 1863-1867.
33. Brandi, M.L., (2009) Microarchitecture, the key to bone quality. Rheumatology (Oxford) 48 (Suppl 4), iv3-iv8.
34. Griffith, J.F., Engelke, K., &, Genant, H.K., (2010) Looking beyond bone mineral density: Imaging assessment of bone quality. Annals of the New York Academy of Sciences, 1192, 45-56.
35. Rehman, Q., Lang, T., Modin, G., et al,. (2002) Quantitative computed tomography of the lumbar spine, not dual x-ray absorptiometry, is an independent predictor of prevalent vertebral fractures in postmenopausal women with osteopenia receiving long-term glucocorticoid and hormone-replacement therapy. Arthritis and Rheumatism, 46, 1292-1297.
36. Lian, K.C., Lang, T.F., Keyak, J.H., et al,. (2005) Differences in hip quantitative computed tomography (QCT) measurements of bone mineral density and bone strength between glucocorticoid-treated and glucocorticoid-naive postmenopausal women. Osteoporosis International, 16, 642-650.
37. Genant, H.K., Delmas, P.D., Chen, P., et al,. (2007) Severity of vertebral fracture reflects deterioration of bone microarchitecture. Osteoporosis International, 18, 69-76.
38. Pothuaud, L., Carceller, P., &, Hans, D., (2008) Correlations between grey-level variations in 2D projection images (TBS) and 3D microarchitecture: applications in the study of human trabecular bone microarchitecture. Bone, 42, 775-787.
39. Chiodini, I., Morelli, V., Masserini, B., et al,. (2009) Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: an Italian multicenter study. Journal of Clinical Endocrinology and Metabolism, 94, 3207-3214.
40. Eller-Vainicher, C., Morelli, V., Ulivieri, F.M., et al,. (2012) Bone quality, as measured by trabecular bone score in patients with adrenal incidentalomas with and without subclinical hypercortisolism. Journal of Bone and Mineral Research, 27, 2223-2230.
41. Vestergaard, P., Lindholm, J., Jorgensen, J.O., et al,. (2002) Increased risk of osteoporotic fractures in patients with Cushing's syndrome. European Journal of Endocrinology, 146, 51-56.
42. Valassi, E., Santos, A., Yaneva, M., et al,. (2011) The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics. European Journal of Endocrinology, 165, 383-392.
43. Van Staa, T.P., Leufkens, H.G., Abenhaim, L., et al,. (2000) Use of oral corticosteroids and risk of fractures. Journal of Bone and Mineral Research, 15, 993-1000.
44. Vestergaard, P., Rejnmark, L., &, Mosekilde, L., (2008) Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures. Calcified Tissue International, 82, 249-257.
45. Godang, K., Ueland, T., &, Bollerslev, J., (1999) Decreased bone area, bone mineral content, formative markers, and increased bone resorptive markers in endogenous Cushing's syndrome. European Journal of Endocrinology, 141, 126-131.
46. Kristo, C., Jemtland, R., Ueland, T., et al,. (2006) Restoration of the coupling process and normalization of bone mass following successful treatment of endogenous Cushing's syndrome: a prospective, long-term study. European Journal of Endocrinology, 154, 109-118.
47. Karavitaki, N., Ioannidis, G., Giannakopoulos, F., et al,. (2004) Evaluation of bone mineral density of the peripheral skeleton in pre- and postmenopausal women with newly diagnosed endogenous Cushing's syndrome. Clinical endocrinology (Oxford), 60, 264-270.
48. van Schoor, N.M., Dennison, E., Lips, P., et al,. (2007) Serum fasting cortisol in relation to bone, and the role of genetic variations in the glucocorticoid receptor. Clinical endocrinology (Oxford), 67, 871-878.
49. Reynolds, R.M., Dennison, E.M., Walker, B.R., et al,. (2005) Cortisol secretion and rate of bone loss in a population-based cohort of elderly men and women. Calcified Tissue International, 77, 134-138.
50. Osella, G., Ventura, M., Ardito, A., et al,. (2012) Cortisol secretion, bone health, and bone loss: a cross-sectional and prospective study in normal non-osteoporotic women in the early postmenopausal period. European Journal of Endocrinology, 166, 855-860.
51. Dennison, E., Hindmarsh, P., Fall, C., et al,. (1999) Profiles of endogenous circulating cortisol and bone mineral density in healthy elderly men. Journal of Clinical Endocrinology and Metabolism, 84, 3058-3063.
52. Lodish, M.B., Hsiao, H.P., Serbis, A., et al,. (2010) Effects of Cushing disease on bone mineral density in a pediatric population. Journal of Pediatrics, 156, 1001-1005.
53. Acharya, S.V., Gopal, R.A., Lila, A., et al,. (2010) Bone age and factors affecting skeletal maturation at diagnosis of paediatric Cushing's disease. Pituitary, 13, 355-360.
54. Francucci, C.M., Pantanetti, P., Garrapa, G.G., et al,. (2002) Bone metabolism and mass in women with Cushing's syndrome and adrenal incidentaloma. Clinical endocrinology (Oxford), 57, 587-593.
55. Civitelli, R., &, Ziambaras, K., (2008) Epidemiology of glucocorticoid-induced osteoporosis. Journal of Endocrinological Investigation, 31, 2-6.
56. Majnik, J., Szucs, N., Patocs, A., et al,. (2004) Effect of single doses of dexamethasone and adrenocorticotrop hormone on serum bone markers in healthy subjects and in patients with adrenal incidentalomas and Cushing's syndrome. Journal of Endocrinological Investigation, 27, 747-753.
57. Sartorio, A., Conti, A., Ferrero, S., et al,. (1998) Evaluation of markers of bone and collagen turnover in patients with active and preclinical Cushing's syndrome and in patients with adrenal incidentaloma. European Journal of Endocrinology, 138, 146-152.
58. Piovesan, A., Terzolo, M., Reimondo, G., et al,. (1994) Biochemical markers of bone and collagen turnover in acromegaly or Cushing's syndrome. Hormone and Metabolic Research, 26, 234-237.
59. Di Somma, C., Pivonello, R., Loche, S., et al,. (2002) Severe impairment of bone mass and turnover in Cushing's disease: comparison between childhood-onset and adulthood-onset disease. Clinical endocrinology (Oxford), 56, 153-158.
60. Szappanos, A., Toke, J., Lippai, D., et al,. (2010) Bone turnover in patients with endogenous Cushing's syndrome before and after successful treatment. Osteoporosis International, 21, 637-645.
61. Sereg, M., Toke, J., Patocs, A., et al,. (2011) Diagnostic performance of salivary cortisol and serum osteocalcin measurements in patients with overt and subclinical Cushing's syndrome. Steroids, 76, 38-42.
62. Cooper, M.S., Syddall, H.E., Fall, C.H., et al,. (2005) Circulating cortisone levels are associated with biochemical markers of bone formation and lumbar spine BMD: the Hertfordshire Cohort Study. Clinical endocrinology (Oxford), 62, 692-697.
63. Pocock, N.A., Eisman, J.A., Dunstan, C.R., et al,. (1987) Recovery from steroid-induced osteoporosis. Annals of Internal Medicine, 107, 319-323.
64. Manning, P.J., Evans, M.C., &, Reid, I.R., (1992) Normal bone mineral density following cure of Cushing's syndrome. Clinical endocrinology (Oxford), 36, 229-234.
65. Arnaldi, G., Angeli, A., Atkinson, A.B., et al,. (2003) Diagnosis and complications of Cushing's syndrome: a consensus statement. Journal of Clinical Endocrinology and Metabolism, 88, 5593-5602.
66. Leong, G.M., Abad, V., Charmandari, E., et al,. (2007) Effects of child- and adolescent-onset endogenous Cushing syndrome on bone mass, body composition, and growth: a 7-year prospective study into young adulthood. Journal of Bone and Mineral Research, 22, 110-118.
67. Dalle Carbonare, L., Arlot, M.E., Chavassieux, P.M., et al,. (2001) Comparison of trabecular bone microarchitecture and remodeling in glucocorticoid-induced and postmenopausal osteoporosis. Journal of Bone and Mineral Research, 16, 97-103.
68. Frost, H.M., (1987) The mechanostat: a proposed pathogenic mechanism of osteoporoses and the bone mass effects of mechanical and nonmechanical agents. Bone and Mineral, 2, 73-85.
69. Resmini, E., Farkas, C., Murillo, B., et al,. (2010) Body composition after endogenous (Cushing's syndrome) and exogenous (rheumatoid arthritis) exposure to glucocorticoids. Hormone and Metabolic Research, 42, 613-618.
70. Szappanos, A., Patocs, A., Toke, J., et al,. (2009) BclI polymorphism of the glucocorticoid receptor gene is associated with decreased bone mineral density in patients with endogenous hypercortisolism. Clinical endocrinology (Oxford), 71, 636-643.
71. Szappanos, A., Patocs, A., Gergics, P., et al,. (2011) The 83,557insA variant of the gene coding 11beta-hydroxysteroid dehydrogenase type 1 enzyme associates with serum osteocalcin in patients with endogenous Cushing's syndrome. Journal of Steroid Biochemistry and Molecular Biology, 123, 79-84.
72. Hwang, J.Y., Lee, S.H., Kim, G.S., et al,. (2009) HSD11B1 polymorphisms predicted bone mineral density and fracture risk in postmenopausal women without a clinically apparent hypercortisolemia. Bone, 45, 1098-1103.
73. Chiodini, I., (2011) Clinical review: diagnosis and treatment of subclinical hypercortisolism. Journal of Clinical Endocrinology and Metabolism, 96, 1223-1236.
74. Morelli, V., Eller-Vainicher, C., Salcuni, A.S., et al,. (2011) Risk of new vertebral fractures in patients with adrenal incidentaloma with and without subclinical hypercortisolism: a multicenter longitudinal study. Journal of Bone and Mineral Research, 26, 1816-1821.
75. Kann, P., Laudes, M., Piepkorn, B., et al,. (2001) Suppressed levels of serum cortisol following high-dose oral dexamethasone administration differ between healthy postmenopausal females and patients with established primary vertebral osteoporosis. Clinical Rheumatology, 20, 25-29.
76. Chiodini, I., Mascia, M.L., Muscarella, S., et al,. (2007) Subclinical hypercortisolism among outpatients referred for osteoporosis. Annals of Internal Medicine, 147, 541-548.
77. Terzolo, M., Pia, A., &, Reimondo, G., (2012) Subclinical Cushing's syndrome: definition and management. Clinical endocrinology (Oxford), 76, 12-18.
78. De Leo, M., Cozzolino, A., Colao, A., et al,. (2012) Subclinical Cushing's syndrome. Best Practice and Research Clinical Endocrinology and Metabolism, 26, 497-505.
79. Scommegna, S., Greening, J.P., Storr, H.L., et al,. (2005) Bone mineral density at diagnosis and following successful treatment of pediatric Cushing's disease. Journal of Endocrinological Investigation, 28, 231-235.
80. Grossman, J.M., Gordon, R., Ranganath, V.K., et al,. (2010) American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care and Research (Hoboken), 62, 1515-1526.
81. Rizzoli, R., Adachi, J.D., Cooper, C., et al,. (2012) Management of glucocorticoid-induced osteoporosis. Calcified Tissue International, 91, 225-243.
82. Keaveny, T.M., Donley, D.W., Hoffmann, P.F., et al,. (2007) Effects of teriparatide and alendronate on vertebral strength as assessed by finite element modeling of QCT scans in women with osteoporosis. Journal of Bone and Mineral Research, 22, 149-157.
83. Keaveny, T.M., Kopperdahl, D.L., Melton, L.J. 3rd, et al,. (2010) Age-dependence of femoral strength in white women and men. Journal of Bone and Mineral Research, 25, 994-1001.
84. Keaveny, T.M., McClung, M.R., Wan, X., et al,. (2012) Femoral strength in osteoporotic women treated with teriparatide or alendronate. Bone, 50, 165-170.
85. Lindholm, J., Juul, S., Jorgensen, J.O., et al,. (2001) Incidence and late prognosis of cushing's syndrome: a population-based study. Journal of Clinical Endocrinology and Metabolism, 86, 117-123.
86. Cortet, B., Cortet, C., Blanckaert, F., et al,. (2001) Quantitative ultrasound of bone and markers of bone turnover in Cushing's syndrome. Osteoporosis International, 12, 117-123.